echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > An unprecedented "obesity crisis"! In 2030, the overweight/obesity rate in China may reach 70%!

    An unprecedented "obesity crisis"! In 2030, the overweight/obesity rate in China may reach 70%!

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Medical Pulse Tong editing and collation, please do not reprint


    Introduction: From 2018 to 2019, the prevalence of overweight/obesity, hypertension and diabetes in adults in China was 51.



    Status: One in every two adults is overweight/obese


    Since the 1970s, China's overall economic level has grown rapidly, and the living standards of residents have improved rapidly, but various complex factors behind it have jointly promoted the increase



    Since the 1990s, the prevalence of obesity in our country has been rising, and obesity has become a major public health problem for both adults and children, with one in two adults currently overweight or obese



    Prediction: In 2030, the proportion of adults overweight/obesity in China may reach 70%


    Recently, based on linear regression analysis of national data, some scholars have made a latest assessment of the prevalence of overweight/obesity in China, and used data analysis methods to predict



    It is predicted that by 2030, the overall prevalence of overweight/obesity among adults in China may reach 70.



    Figure 1 Trend chart of overweight/obesity in China (including predictions)

    Note: Overweight: BMI 24.



    Prediction: In 2030, the number of people with diabetes may exceed 200 million, and the number of people with hypertension may exceed 400 million


    If effective interventions are not implemented in the near future, the burden of obesity and its comorbidities will continue to increase
    .

    Using nationally representative data collected since the 1990s, including the 2015 China National Nutrition and Health Survey, we predicted the prevalence of hypertension and type 2 diabetes by 2030 and the number of people with these diseases (Figure 2
    ).

    Through linear regression analysis, by 2030, the prevalence of hypertension and diabetes in China may reach 35.
    4% and 18.
    5% respectively, and the number may reach 416 million and 218 million
    .

    Figure 2 Prevalence trend of hypertension and type 2 diabetes in China (including predictions)

    Note: Hypertension is defined as mean SBP≥140mmHg or average DBP≥90mmHg or previously diagnosed by a doctor as hypertension or self-reported use of antihypertensive drugs; T2DM is defined as an empty-stomach blood glucose level of ≥ 7.
    0 mmol/L, a 2-hour blood glucose level of ≥ 11.
    1 mmol/L (OGTT 2h, after 75 g of glucose), or previously confirmed
    .

    Curbing the obesity crisis is urgent!

    Predictive analysis suggests that the health burden of obesity, including obesity-related hypertension and diabetes, is likely to continue to increase over the next decade and will reach very high levels
    by 2030.

    In 2018, the prevalence of overweight/obesity, hypertension, and T2DM among Chinese adults was 51.
    2%, 27.
    5%, and 12.
    4%,
    respectively.

    By 2030, the prevalence is expected to be 70.
    5%, 35.
    4% and 18.
    5%, respectively, and the number of adults will be 810.
    65 million, 416.
    47 million and 217.
    64 million
    , respectively.

    At present, the health burden caused by obesity in China is very high, and this form is still likely to deteriorate sharply in the next few years, and there is an urgent need for positive population-based specific interventions to combat the growing obesity epidemic
    .

    References: Sun X, Yan AF, Shi Z, et al.
    Health consequences of obesity and projected future obesity health burden in China.
    Obesity(Silver Spring,Md).
    2022 Sep,30(9): 1724-1751.
    DOI: 10.
    1002/oby.
    23472,PMID:36000246

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.